Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
Add more filters











Database
Language
Publication year range
1.
Metabolism ; 47(4): 474-7, 1998 Apr.
Article in English | MEDLINE | ID: mdl-9550548

ABSTRACT

To investigate the effects of thyroid hormone and testosterone on 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1), we measured changes in hepatic 11beta-dehydrogenase activity and its mRNA levels in pubertal methimazole (MMI)-induced hypothyroid male rats following treatment with thyroxine ([T4] 50 microg/kg/d) or testosterone (250 microg/d) for 14 days. Hypothyroidism in male rats markedly reduced hepatic 11beta-HSD1 mRNA levels and serum testosterone concentrations (P < .01). Subcutaneous injection of T4 in the hypothyroid rats significantly (P < .01) increased hepatic 11beta-HSD1 mRNA to approximately normal levels and simultaneously increased serum testosterone levels. However, the same daily dose of T4 administered to castrated male hypothyroid rats for 14 days did not elevate hepatic 11beta-HSD1 activity. Treatment with testosterone for 14 days in castrated hypothyroid male rats and rats without gonadectomy significantly (P < .01) increased the enzyme activity without administration of T4. Variations in hepatic 11beta-HSD1 activity were demonstrated to be accompanied by changes in serum testosterone levels in the rats following alteration of the thyroid hormone state. These results suggest that the effect of T4 in increasing the subnormal 11beta-HSD1 gene expression in hypothyroid male rats is mediated by its ability to increase testosterone production in these rats, because in castrated hypothyroid rats, T4 does not elevate 11beta-HSD1 gene expression.


Subject(s)
Hydroxysteroid Dehydrogenases/genetics , Hypothyroidism/drug therapy , Liver/enzymology , RNA, Messenger/metabolism , Sexual Maturation/physiology , Testosterone/pharmacology , Thyroxine/pharmacology , 11-beta-Hydroxysteroid Dehydrogenases , Animals , Basal Metabolism , Hypothyroidism/metabolism , Male , Orchiectomy , Rats , Rats, Sprague-Dawley , Testis/physiology , Thyroxine/physiology
2.
Endocr J ; 44(2): 275-81, 1997 Apr.
Article in English | MEDLINE | ID: mdl-9228463

ABSTRACT

We followed up a girl with the neonatal form of Bartter's syndrome for sixteen years and determined the sensitivity to angiotensin II before and during the indomethacin treatment. A 4-month-old girl was admitted to our hospital, because of severe hypokalemia and growth retardation. Initially we treated her with spironolactone and potassium supplements. This treatment increased plasma potassium levels and her growth. At the age of one year she was diagnosed as having Bartter's syndrome. Since then she has been treated with indomethacin at an initial dose of 3 mg/kg/day combined with spironolactone and potassium. After the start of the indomethacin treatment, her growth increased dramatically, and her final height was normal adult height. Her puberty developed normally and menarche occurred at the age of 12 years. Levels of serum sodium, chloride, plasma aldosterone and urinary prostaglandin E2 were also normalized. Levels of angiotensin I and II were improved but not within the normal range, but plasma potassium levels slightly decreased after plasma aldosterone levels were normalized and did not change during the treatment period. Plasma renin activity remained high until about the age of 8 years, after which it decreased to almost within the normal range. At 5 months after the start of indomethacin (3 mg/kg/day), her vascular sensitivity to angiotensin II had been improved, and after 2 years and 5 months, her vascular sensitivity was further improved. At this time renin activity had decreased after angiotensin II infusion, but plasma aldosterone did not change. At the age of 16 years (dose of indomethacin: 0.5 mg/kg/day), plasma aldosterone increased after angiotensin II infusion. These data suggest that indomethacin and spironolactone are effective treatments for the neonatal form of Bartter's syndrome, especially during childhood.


Subject(s)
Bartter Syndrome/drug therapy , Bartter Syndrome/physiopathology , Angiotensin I/blood , Angiotensin II/blood , Bartter Syndrome/diagnosis , Female , Follow-Up Studies , Growth/drug effects , Humans , Indomethacin/therapeutic use , Infant , Potassium/blood , Potassium/therapeutic use , Spironolactone/therapeutic use
3.
Life Sci ; 59(3): 227-34, 1996.
Article in English | MEDLINE | ID: mdl-8699933

ABSTRACT

11 beta-hydroxysteroid dehydrogenase (11 beta-HSD) is a microsomal enzyme present in the peripheral tissues of the rat, including the liver, and is mediated by a number of factors in animal in vivo studies. However, the effect of peptide hormones and glucocorticoids on the activity of 11 beta-HSD in isolated rat hepatocytes is not clear. To investigate these effects, we determined 11 beta-HSD activity in a primary culture of rat hepatocytes by adding various concentrations of growth hormone, insulin and dexamethasone (Dex). 11 beta-HSD activity increased significantly after treatment with Dex (10(-9)M-10(-6)M) for 48h. Dex (100nM) treated hepatocytes, incubated for 12h to 48h, resulted in a significant two-to four-fold rise in 11 beta-HSD activity compared to control (p < 0.01), which was in contrast to GH (10(-9)M-10(-6)M) and insulin (10(-8)M-10(-5)M), which inhibited 11 beta-HSD activity (p < 0.05). These results suggest that the 11 beta-HSD of rat hepatocytes is under multifactorial regulation; Dex stimulates and GH and insulin inhibit 11 beta-HSD activity in primary cultures of rat hepatocytes.


Subject(s)
Dexamethasone/pharmacology , Growth Hormone/pharmacology , Hydroxysteroid Dehydrogenases/pharmacology , Insulin/pharmacology , Liver/drug effects , 11-beta-Hydroxysteroid Dehydrogenases , Animals , Cells, Cultured , Male , Rats , Rats, Sprague-Dawley , Time Factors
4.
Horm Metab Res ; 28(1): 23-6, 1996 Jan.
Article in English | MEDLINE | ID: mdl-8820990

ABSTRACT

The etiology of congenital generalized lipodystrophy (CGL) is unknown, but one of the clinical features is an accelerated rate of growth. In order to determine whether this abnormality is related to an abnormality of the GH or the IGF-I gene, we studied the DNA of lymphocytes of a girl with CGL. The IGF-I gene autoradiographic patterns of this patient were found not to differ from those of normal subjects, but after BamHI digestion, this patient's GH gene cluster had an aberrant 5.7 kb fragment in addition to the constant 8.3, 6.7, 5.3, 3.8, 2.9 kg fragments. The new 5.7 kb fragment was not detected in any of 60 unrelated Japanese individuals. In conclusion, the CGL patient carries an abnormal GH gene cluster, but further studies are needed to clarify whether this abnormal fragment is specific to CGL or just a rare polymorphic fragment.


Subject(s)
Growth Hormone/genetics , Lipodystrophy/genetics , Multigene Family/genetics , Autoradiography , DNA/analysis , Deoxyribonuclease BamHI , Female , Growth Disorders/genetics , Growth Hormone/blood , Hormones/blood , Humans , Infant , Insulin-Like Growth Factor I/genetics , Lipodystrophy/blood , Lipodystrophy/congenital , Lymphocytes/chemistry , Lymphocytes/metabolism , Polycystic Ovary Syndrome/complications , Polycystic Ovary Syndrome/diagnostic imaging , Restriction Mapping , Ultrasonography
5.
Acta Paediatr Jpn ; 37(3): 405-8, 1995 Jun.
Article in English | MEDLINE | ID: mdl-7645400

ABSTRACT

A 12 year old boy was admitted to our hospital because of short stature. From the age of 7, his growth velocity decreased and he manifested intolerance to low temperatures, hoarseness, dry skin, and slowness of thought and physical movement. On admission, his height was 129.8 cm (-3 s.d.) and his body weight was 43.2 kg (-0.5 s.d.). His clinical features also included relaxation phase of tendon reflexes, periorbital puffiness and cold skin but no struma. His bone age was 9 years. His serum thyroxine (T4), triiodothyronine (T3), free T4 and free T3 were low, while his thyrotropin was high. He was positive for antithyroglobulin antibodies, antimicrosomal antibodies, and TSH-binding inhibitor immunoglobulins. He was diagnosed as having atrophic thyroiditis. We also determined the HLA haplotypes of his family members. His father's HLA haplotypes were A2, BW61(a) and A24, BW52(b), while his mother's haplotypes were A24, BW52(c) and A30, BW60(d). The HLA haplotypes of both the patient and his younger brother showed a and d, while the patient's elder brother's HLA haplotypes showed b and c. His family members all had normal thyroid function, but his father was positive for antimicrosomal antibodies. In summary, we describe a rare case where the onset of hypothyroidism was prepubertal, where the pathogenesis may have involved TSH-receptor blocking antibodies, and where the inheritance of the disease may have been from the paternal side of the family.


Subject(s)
Autoantibodies/immunology , Immunoglobulin Idiotypes , Receptors, Thyrotropin/immunology , Thyroiditis, Autoimmune/immunology , Age of Onset , Child , Dwarfism/etiology , HLA Antigens/analysis , Humans , Immunoglobulins, Thyroid-Stimulating , Male , Pedigree , Thyroiditis, Autoimmune/complications , Thyroiditis, Autoimmune/genetics
6.
J Steroid Biochem Mol Biol ; 48(5-6): 557-61, 1994 Apr.
Article in English | MEDLINE | ID: mdl-8180119

ABSTRACT

Steroid 21-hydroxylase activity has been identified in many tissues, including liver. But it is possible that the enzyme found in the liver is different from adrenal 21-hydroxylase. In the adrenal cortex, steroid 21-hydroxylase activity is increased by corticotropin (ACTH); the effect of ACTH is mediated by cyclic AMP (cAMP), and presumably involves a cAMP-dependent protein kinase (PKA). It is not yet clear, however, how extra-adrenal steroid 21-hydroxylase activity is regulated. In the present study, we examined the effect of N6,2'-O-dibutyryl adenosine 3',5'-cyclic monophosphate (dbcAMP), forskolin, N-[2-(methylamino)ethyl]5-isoquinolinesulfonamide (H-8) and 12-O-tetradecanoylphorbol-13-acetate (TPA) on steroid 21-hydroxylase activity in primary cultures of rat hepatocytes to determine the nature of regulation of extra-adrenal steroid 21-hydroxylase activity. Steroid 21-hydroxylase activity in hepatocytes incubated with 10(-11) M dbcAMP for 24 h was 1.6 times higher than that in control hepatocytes untreated with dbcAMP. On the other hand, steroid 21-hydroxylase activity decreased by 20 and 50% when the cells were incubated with 10(-5) and 10(-3) M dbcAMP, respectively. The stimulatory effect of 10(-11) M dbcAMP was not blocked by 10(-5) M H-8 (PKA inhibitor), but the inhibitory effect of 10(-5) or 10(-3) M cAMP was. TPA did not alter the activity of steroid 21-hydroxylase. These findings indicate that the steroid 21-hydroxylase in rat liver is regulated by mechanisms different from those in the adrenal glands.


Subject(s)
Bucladesine/pharmacology , Liver/drug effects , Steroid 21-Hydroxylase/metabolism , Animals , Cells, Cultured , Colforsin/pharmacology , Isoquinolines/pharmacology , Liver/cytology , Liver/enzymology , Male , Protein Kinase C/antagonists & inhibitors , Rats , Rats, Sprague-Dawley , Steroid 21-Hydroxylase/drug effects , Tetradecanoylphorbol Acetate/pharmacology
7.
Jpn J Hum Genet ; 38(2): 225-8, 1993 Jun.
Article in English | MEDLINE | ID: mdl-8358046

ABSTRACT

We have experienced the case of a 10-year-old boy who had Goldenhar syndrome accompanied by growth hormone (GH) deficiency. His height increased after treatment with growth hormone was administered. We found no untoward effects of the hormone and we consider that treatment with GH is useful for patients who present with Goldenhar syndrome associated with growth hormone deficiency.


Subject(s)
Goldenhar Syndrome/complications , Growth Hormone/deficiency , Child , Goldenhar Syndrome/drug therapy , Growth Hormone/therapeutic use , Humans , Male , Seizures/complications , Seizures/drug therapy , Valproic Acid/therapeutic use
8.
Acta Paediatr Jpn ; 33(3): 381-3, 1991 Jun.
Article in English | MEDLINE | ID: mdl-1664635

ABSTRACT

Angiotensin-induced hypertension chemotherapy (IHC) was investigated in six children with the following advanced malignancies: hepatocellular carcinoma, extraskeletal Ewing's sarcoma, sacrococcygeal malignant teratoma, small round cell tumor of the chest wall, hepatoblastoma and osteogenic sarcoma. Partial response was achieved in three of these patients, two showed no change, and in one IHC was used as adjuvant chemotherapy. The side effects of IHC were minimal and tolerable. Angiotensin-IHC may provide a new approach to pediatric cancer chemotherapy.


Subject(s)
Angiotensin II/administration & dosage , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Hypertension/chemically induced , Neoplasms/drug therapy , Adolescent , Bone Neoplasms/blood supply , Bone Neoplasms/drug therapy , Bone Neoplasms/pathology , Carcinoma, Hepatocellular/blood supply , Carcinoma, Hepatocellular/drug therapy , Carcinoma, Hepatocellular/pathology , Child , Child, Preschool , Coccyx , Female , Humans , Infant , Infusions, Intravenous , Liver Neoplasms/blood supply , Liver Neoplasms/drug therapy , Liver Neoplasms/pathology , Lung Neoplasms/blood supply , Lung Neoplasms/drug therapy , Lung Neoplasms/etiology , Lung Neoplasms/secondary , Male , Neoplasm Staging , Neoplasms/blood supply , Neoplasms/pathology , Sacrum , Thoracic Neoplasms/drug therapy
9.
Cancer ; 64(1): 43-51, 1989 Jul 01.
Article in English | MEDLINE | ID: mdl-2731119

ABSTRACT

The authors describe a 14-year-old girl with small round cell tumor originating in the chest wall analyzed by the extensive studies including light and electron microscopic examination, histochemical study, immunochemical study, cytogenetics, and gene analysis. A cell line producing carcinoembryonic antigen (CEA) and neuron-specific enolase (NSE) has been established from pleural effusion of the pulmonary metastatic tumor. Cytogenetic analysis disclosed a reciprocal translocation (11;22)(q24;q12). Additionally, immunocytochemical studies demonstrated that CEA, NSE, vimentin, cytokeratin, and epithelial membrane antigens are positive, but desmin and S-100 protein are negative. Although neurofilament was negative in the pulmonary metastatic tumor cells, it became positive in cell line in vitro. These results suggest that this tumor may be derived from the primitive and pluripotential cells, differentiating into mesenchymal, epithelial, and neural features in variable proportions.


Subject(s)
Thoracic Neoplasms/pathology , Adolescent , Animals , Carcinoembryonic Antigen/analysis , DNA, Neoplasm/analysis , Female , Humans , Mice , Mice, Nude , Neoplastic Stem Cells , Oncogenes , Phosphopyruvate Hydratase/analysis , Thoracic Neoplasms/genetics , Thoracic Neoplasms/metabolism , Translocation, Genetic , Tumor Cells, Cultured
SELECTION OF CITATIONS
SEARCH DETAIL